Search
Displaying 161–170 of 1066 results
-
ARVO 2024 Highlight: New Gene Linked to RP in People with African Ancestry
Research NewsThe discovery will help geneticists diagnose more RP patients with African descent.
-
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Research NewsMutations in PDE6B are a leading cause of retinitis pigmentosa.
-
Disease
Thyroid Eye Disease (TED) is a rare lifelong, autoimmune condition that affects the eyes and can get worse over time. When you have TED, your body’s immune system mistakenly attacks the tissue behind your eyes, which may cause inflammation and swelling of the muscle and fat behind the eye.
-
VISIONS 2024, the global conference (June 20–21, 2024) of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
Beacon Stories
In honor of the upcoming Mother’s Day, New York Times, USA Today, and Wall Street Journal bestselling author Jennifer Probst is sharing her personal story of her son’s diagnosis with Stargardt disease.
-
Eye on the Cure Podcast | Episode 65: Matthew Whitaker
Eye on the CureMatthew Whitaker talks to host Ben Shaberman about his remarkable achievements and success as a young jazz pianist and composer.
-
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Foundation Fighting Blindness To Host Annual 2024 Gala Night for Sight
Foundation NewsThe May 9th gala will raise awareness and fund research leading to treatments and cures for blinding diseases.
-
VISIONS 2024, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
